Co-delivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells

• 作 者: YingLu;ZhirongGong;JieGao;YanqiangZhong;
• 机 构: Department of Pharmaceutical Science, Second Military Medical University, Shanghai,China
• 出 处: 第二届全国生物颗粒学术研讨会、第三届国际工业药学和临床药学研讨会暨第一届岭南国际药学大会
• 发表日期: 2015年期

　　To develop salinomycin-loaded nanoliposomes (SLN), doxorubicin-loaded nanoliposomes (DLN) and nanoliposomes co-delivering salinomycin and doxorubicin (SDLN) to target both liver cancer cells and cancer stem cells (CSCs).The characterization and anti-tumour activity of SLN, DLN and SDLN were evaluated The doxorubicin/salinomycin mole ratio of 1∶1 had the best synergistic combination index (CI) value, and was chosen as the drug ratio in SDLN.SDLN could maintain the drug ratio between1∶1 to 3∶1 in 12 h in vivo.SDLN and SLN + DLN showed the best turnour inhibitory rate, and could significantly decrease the percentage of liver CSCs in vivo.SDLN and SLN + DLN may serve as an effective approach to treat liver cancer.